Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegileridine for remifentanil-induced hyperalgesia after laparoscopic surgery
ChiCTR2600121314Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tegileridine in Remifentanil-induced hyperalgesia (RIH), postoperative pain, None and 1 more (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoints: Pain threshold around surgical incision at 24 hours postoperatively, Pain threshold on medial aspect of non-dominant forearm at 24 hours postoperatively and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
tegileridine
03
Conditions
Remifentanil-induced hyperalgesia (RIH)postoperative painExpanded pain area
Beyond the preview
Go deeper on ChiCTR2600121314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121314.